Novartis Bets $2.9B on PTC Therapeutics' Huntington’s Disease Drug Breakthrough

Warren, NJ, December 2, 2024 (Reuters) -- Novartis is acquiring PTC Therapeutics' Huntington’s disease drug, PTC518, for up to $2.9 billion. Mid-stage trial results show the drug reduces the harmful Huntingtin protein by 43%, a development that has driven up PTC's share price. This deal underscores Novartis' commitment to advancing treatments for rare neurological disorders.

Read full article here.